Copyright
©The Author(s) 2025.
World J Hepatol. Mar 27, 2025; 17(3): 104715
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.104715
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.104715
Table 1 Currently common experimental drugs targeting glucose transporter proteins
Ref. | Name | Target GLUTs | Ways to interfere with GLUT action |
Ebstensen and Plagemann[86] | Cytochalasin B | Competition with GLUTs for binding sites | Reduces glucose supply to cancer cells |
Ceballos et al[88] | Glupin | GLUT1, and GLUT3 | Inhibition of glucose uptake |
Karageorgis et al[89] | Chromopynones | GLUT1, and GLUT3 | Inhibition of glucose uptake |
Reckzeh et al[90] | Glutor | GLUT1, 2, and 3 | Inhibits glycolytic processes |
Guo et al[91] | Rapaglutin A | GLUT1, 3, and 4 | Stimulates insulin secretion and inhibits GLUT uptake |
Wood et al[93] | Fasentin | GLUT1 | Inhibits glycolytic processes |
Siebeneicher et al[94] | WZB117, BAY-876 | GLUT1 | Enhancing the sensitivity of HCC cells to chemotherapeutic agents |
- Citation: Ruan Z, Wang Y, Shi L, Yang XJ. Progress of research on glucose transporter proteins in hepatocellular carcinoma. World J Hepatol 2025; 17(3): 104715
- URL: https://www.wjgnet.com/1948-5182/full/v17/i3/104715.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i3.104715